105 related articles for article (PubMed ID: 29549836)
1. Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors.
La Pietra V; Sartini S; Botta L; Antonelli A; Ferrari SM; Fallahi P; Moriconi A; Coviello V; Quattrini L; Ke YY; Hsing-Pang H; Da Settimo F; Novellino E; La Motta C; Marinelli L
Eur J Med Chem; 2018 Apr; 150():491-505. PubMed ID: 29549836
[TBL] [Abstract][Full Text] [Related]
2. Selective RET kinase inhibition for patients with RET-altered cancers.
Subbiah V; Velcheti V; Tuch BB; Ebata K; Busaidy NL; Cabanillas ME; Wirth LJ; Stock S; Smith S; Lauriault V; Corsi-Travali S; Henry D; Burkard M; Hamor R; Bouhana K; Winski S; Wallace RD; Hartley D; Rhodes S; Reddy M; Brandhuber BJ; Andrews S; Rothenberg SM; Drilon A
Ann Oncol; 2018 Aug; 29(8):1869-1876. PubMed ID: 29912274
[TBL] [Abstract][Full Text] [Related]
3. Identification of two novel RET kinase inhibitors through MCR-based drug discovery: design, synthesis and evaluation.
Frett B; Moccia M; Carlomagno F; Santoro M; Li HY
Eur J Med Chem; 2014 Oct; 86():714-23. PubMed ID: 25232968
[TBL] [Abstract][Full Text] [Related]
4. Molecular Modelling Studies on Pyrazole Derivatives for the Design of Potent Rearranged during Transfection Kinase Inhibitors.
Bhujbal SP; Keretsu S; Cho SJ
Molecules; 2021 Jan; 26(3):. PubMed ID: 33525725
[TBL] [Abstract][Full Text] [Related]
5. The Evolving Treatment Landscape of Medullary Thyroid Cancer.
Laganà M; Cremaschi V; Alberti A; Vodopivec Kuri DM; Cosentini D; Berruti A
Curr Treat Options Oncol; 2023 Dec; 24(12):1815-1832. PubMed ID: 37979019
[TBL] [Abstract][Full Text] [Related]
6. Management of Advanced Medullary Thyroid Carcinoma: Current Systemic Therapy Options.
Jara MA
Crit Rev Oncog; 2024; 29(3):83-90. PubMed ID: 38683155
[TBL] [Abstract][Full Text] [Related]
7. Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors.
Acharya B; Saha D; Garcia Garcia N; Armstrong D; Jabali B; Hanafi M; Frett B; Ryan KR
Bioorg Med Chem; 2024 May; 106():117749. PubMed ID: 38744018
[TBL] [Abstract][Full Text] [Related]
8. Thyroid C-Cell Biology and Oncogenic Transformation.
Cote GJ; Grubbs EG; Hofmann MC
Recent Results Cancer Res; 2015; 204():1-39. PubMed ID: 26494382
[TBL] [Abstract][Full Text] [Related]
9. Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology.
Frett B; Carlomagno F; Moccia ML; Brescia A; Federico G; De Falco V; Admire B; Chen Z; Qi W; Santoro M; Li HY
Angew Chem Int Ed Engl; 2015 Jul; 54(30):8717-21. PubMed ID: 26126987
[TBL] [Abstract][Full Text] [Related]
10. Anilinoquinazoline inhibitors of the RET kinase domain-Elaboration of the 7-position.
Jordan AM; Begum H; Fairweather E; Fritzl S; Goldberg K; Hopkins GV; Hamilton NM; Lyons AJ; March HN; Newton R; Small HF; Vishwanath S; Waddell ID; Waszkowycz B; Watson AJ; Ogilvie DJ
Bioorg Med Chem Lett; 2016 Jun; 26(11):2724-9. PubMed ID: 27086121
[TBL] [Abstract][Full Text] [Related]
11. The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity.
Newton R; Bowler KA; Burns EM; Chapman PJ; Fairweather EE; Fritzl SJR; Goldberg KM; Hamilton NM; Holt SV; Hopkins GV; Jones SD; Jordan AM; Lyons AJ; Nikki March H; McDonald NQ; Maguire LA; Mould DP; Purkiss AG; Small HF; Stowell AIJ; Thomson GJ; Waddell ID; Waszkowycz B; Watson AJ; Ogilvie DJ
Eur J Med Chem; 2016 Apr; 112():20-32. PubMed ID: 26874741
[TBL] [Abstract][Full Text] [Related]
12. Antitumor Activity of RXDX-105 in Multiple Cancer Types with
Li GG; Somwar R; Joseph J; Smith RS; Hayashi T; Martin L; Franovic A; Schairer A; Martin E; Riely GJ; Harris J; Yan S; Wei G; Oliver JW; Patel R; Multani P; Ladanyi M; Drilon A
Clin Cancer Res; 2017 Jun; 23(12):2981-2990. PubMed ID: 28011461
[No Abstract] [Full Text] [Related]
13. Generating Potential RET-Specific Inhibitors Using a Novel LSTM Encoder-Decoder Model.
Liu L; Zhao X; Huang X
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397034
[TBL] [Abstract][Full Text] [Related]
14. Targeting the RET tyrosine kinase in neuroblastoma: A review and application of a novel selective drug design strategy.
Steen EA; Basilaia M; Kim W; Getz T; Gustafson JL; Zage PE
Biochem Pharmacol; 2023 Oct; 216():115751. PubMed ID: 37595672
[TBL] [Abstract][Full Text] [Related]
15. [Systemic therapies for advanced thyroid cancer - an update].
Brandenburg T; Machlah YM; Führer-Sakel D
Dtsch Med Wochenschr; 2023 Nov; 148(22):1412-1418. PubMed ID: 37918424
[TBL] [Abstract][Full Text] [Related]
16. A Caged Ret Kinase Inhibitor and its Effect on Motoneuron Development in Zebrafish Embryos.
Bliman D; Nilsson JR; Kettunen P; Andréasson J; Grøtli M
Sci Rep; 2015 Aug; 5():13109. PubMed ID: 26300345
[TBL] [Abstract][Full Text] [Related]
17. Design and Synthesis of Novel Thieno[3,2-
La Monica G; Pizzolanti G; Baiamonte C; Bono A; Alamia F; Mingoia F; Lauria A; Martorana A
ACS Omega; 2023 Sep; 8(38):34640-34649. PubMed ID: 37779971
[TBL] [Abstract][Full Text] [Related]
18. Identification of selective inhibitors of RET and comparison with current clinical candidates through development and validation of a robust screening cascade.
Watson AJ; Hopkins GV; Hitchin S; Begum H; Jones S; Jordan A; Holt S; March HN; Newton R; Small H; Stowell A; Waddell ID; Waszkowycz B; Ogilvie DJ
F1000Res; 2016; 5():1005. PubMed ID: 27429741
[TBL] [Abstract][Full Text] [Related]
19. Crowdsourced identification of multi-target kinase inhibitors for RET- and TAU- based disease: The Multi-Targeting Drug DREAM Challenge.
Xiong Z; Jeon M; Allaway RJ; Kang J; Park D; Lee J; Jeon H; Ko M; Jiang H; Zheng M; Tan AC; Guo X; ; Dang KK; Tropsha A; Hecht C; Das TK; Carlson HA; Abagyan R; Guinney J; Schlessinger A; Cagan R
PLoS Comput Biol; 2021 Sep; 17(9):e1009302. PubMed ID: 34520464
[TBL] [Abstract][Full Text] [Related]
20. Discovery and Optimization of wt-RET/KDR-Selective Inhibitors of RET
Newton R; Waszkowycz B; Seewooruthun C; Burschowsky D; Richards M; Hitchin S; Begum H; Watson A; French E; Hamilton N; Jones S; Lin LY; Waddell I; Echalier A; Bayliss R; Jordan AM; Ogilvie D
ACS Med Chem Lett; 2020 Apr; 11(4):497-505. PubMed ID: 32292556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
